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Introduction. Increased preoperative platelet and neutrophil counts are risk factors for decreased survival in several diﬀerent
malignancies. Our aim was to investigate the relationship between overall or disease-free survival after resection of CRLM
and the preoperative haematological parameters. Methods. We reviewed a cohort of 140 patients who underwent resection of
CRLM with curative intent, utilising prospectively maintained databases. Patient demographics, operative details, FBC, CRP,
INR, histopathology results, and survival data were examined. Kaplan-Meier survival and Cox regression analyses were used to
determine the impact of all variables on survival. Results. 140 patients (96 males) with a median age of 67 years (range 33–82 years)
underwent resection of CRLM. A signiﬁcant correlation was exhibited between preoperative platelet count and neutrophil count
(rho = 0.186, P = .028). When modelled as continuous covariates in a Cox regression hazards, an increased preoperative platelet
(P = .02) and neutrophil counts (P ≤ .001) were signiﬁcantly associated with overall survival. Of the haematological parameters
assessedonlypreoperativeplateletcountshowedastrongtrendofassociationwithdiseasefreesurvival;howeverthisfailedtoreach
statistical signiﬁcance (P = .076). Conclusions. Increased preoperative platelet and neutrophil counts are independent risk factors
for decreased survival in patients undergoing resection of CRLM in our series of patients. These ﬁndings require validation in
larger studies to determine their relationship with survival. Further research into the role of these cell types in tumour progression,
particularly in the development and inhibition of angiogenesis, is warranted.
Copyright © 2009 K. Dajani et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The utility of surgical resection of colorectal liver metastases
(CRLM) is clearly established. A large number of substantial
prospective and retrospective studies consistently show ﬁve-
year survival rates following liver resection of 30%–50%,
depending on selection criteria [1]. Recently, a shift has
occurred in the criteria used for assessing resectability, from
morphological criteria to those based on whether a macro-
scopicallyandmicroscopicallycomplete(R0)resectionofthe
livercanbeachievedwhileleavingsuﬃcientfunctioningliver
(the “future liver remnant”) [2–6].
This, however, does not give useful information on
prognosis following resection. Several studies have identiﬁed
possible preoperative prognostic factors for survival includ-
ing stage of primary tumour, preoperative carcinoembryonic
antigen (CEA) level, disease free interval, size and number of
hepatic metastases, and the presence of extrahepatic disease
[7]. A systematic review of these studies has identiﬁed a
worse prognosis and earlier tumour recurrence associated
with resection margin involvement, lymph node metastasis,
and the presence of bilobar liver disease [1]. However, little
is known about the inﬂuence of preoperative haematological
factors on prognosis following CRLM resection.
Preoperative haematological parameters and markers of
the systemic inﬂammatory response have been correlated
with prognosis in several other malignancies. An increased
preoperative platelet count has been identiﬁed as an adverse
prognostic indicator in bronchial [8], gastric [9], gynaeco-
logical malignancies [10, 11], and colorectal cancer [12].
It has also been shown to be an independent prognostic
indicator of survival in patients undergoing resections for
squamous cell carcinoma of the oesophagus [13]a n da d e n o -
carcinoma of the pancreas [14, 15]. Similarly, lymphocyte
count has been identiﬁed as a prognostic indicator in gastric
[16] and breast malignancy [17]. The C-reactive protein2 HPB Surgery
(CRP), a marker of local and systemic inﬂammation, is
also related to survival. A raised CRP has been associated
with a poorer prognosis in patients with gastro-oesophageal,
colorectalcancer,andCRLM[18–20].Apossibleexplanation
lies in the process of tumour angiogenesis, which is a com-
plex interaction between both host and tumour involving
pro- and antiangiogenic factors.
The aim of this study was to investigate the relationship
betweensurvivalafterresectionofCRLMandroutinepreop-
erative blood tests (FBC, CRP, and INR), whose oncological
signiﬁcance may not be fully appreciated.
2. Methods
We reviewed a cohort of 140 patients who had undergone
a liver resection for CRLM with curative intent between
January 2000 and November 2006 utilising a prospectively
maintained database. Additional information was obtained
from hospital notes and laboratory reports where required.
This patient series represents a single consultant surgeon’s
consecutive caseload for CRLM resections during this
period.
Data on the following variables were obtained: patient
demographics, operative details including those of the
primary bowel and secondary hepatic resections, tumour
stage, histological conﬁrmation of CRLM, margin status,
and hepatic nodal status. Initial Dukes stage, perioperative
morbidity (e.g., blood loss, transfusion status, length of stay,
and complications), preoperative laboratory investigations
(haemoglobin, total and diﬀerential white cell count, platelet
count, INR, and CRP), survival (disease free survival and
overall survival), and follow-up data were also recorded.
Patients were excluded if no follow-up data beyond hospital
admission was available (unless they died during their
admission) and if they had undergone a noncurative proce-
dure. Hepatic resection was performed using the Cavitron
Ultrasonic Surgical Aspirator (CUSA) and argon plasma
coagulation. Intermittent Pringle manoeuvre (of 15 minutes
of ischemia followed by 5 minutes of reperfusion) was used
only when deemed necessary. Patients were followed-up at
HPB specialist clinics. Median follow-up was 21 months
(range 1–82 months).
2.1. Statistical Analysis. Kaplan-Meier analysis with logrank
testing was used for univariate analyses, in order to assess
the association between time to death (overall survival),
or tumour recurrence (disease free survival), and each of
the categorical predictor variables of interest. Correlation
between two continuous datasets was analysed with Spear-
man’s rank correlation. The initial univariate analysis was
performed using Cox proportional hazards regression for
each of the haematological variables of interest. These were
modelled as continuous covariates for both univariate and
multivariate analyses to more reliably describe their prog-
nostic value [21]. Kaplan-Meier curves were generated to
illustrate the survival trends according to the haematological
parameters of interest. Variables that showed a trend for
association with survival (P<. 3) were selected for inclusion
in the ﬁnal multivariate Cox proportional hazards model
[22].
3. Results
3.1. Patient Demographics and Outcome. Table 1 details
the demographic and tumour characteristics of the study
population. 140 patients who underwent liver resection for
CRLM with curative intent were included in this analysis.
T h em e d i a na g ew a s6 7y e a r s( r a n g e3 3t o8 2y e a r s ) .9 6w e r e
males. Median disease free interval (time interval between
initial colorectal resection and diagnosis of CRLM) is 6.25
months (range 0–64 months). 62 patients had synchronous
CRLM.Synchronoustumoursaredeﬁnedasthosediagnosed
within three months of the initial colorectal resection.
Tumour recurrence occurred in 71 patients at local and
distant sites during follow-up. 53 patients had recurrence
in the liver or in the lungs; the remainder occurred in the
pelvis, bones, brain, and nodal recurrence. Median time to
recurrence, disease free survival, was 23 months (range of 2–
69months).Themedianoverallsurvivalfortheentirecohort
was 41 months (range 1–82 months).
The overall 30 days mortality for the entire cohort was 7
patients. Postoperative complications occurred in 23.4% of
patients. 118 patients had operative blood loss of <500mls,
16 patients had blood loss of 500–1000mL, and 4 patients
had >1000ml of operative blood loss. 9 patients required
either intra- or postoperative blood transfusion.
3.2. Inﬂuence of Preoperative Haematological Factors on Sur-
vival. The distribution and prognostic relevance of preoper-
ative haematological parameters are summarised in Table 2.
These factors were analysed as continuous variables for uni-
variate Cox proportional hazards regression. Kaplan-Meier
cumulativesurvivalcurvestoillustratetheserelationshipsare
shown in Figure 1. There was signiﬁcant correlation between
preoperativeplateletandneutrophilcount(Spearman,rho =
0.186, P = .028).
Platelet count (P = .013), lymphocyte count (P = .022),
neutrophil count (P< . 001), CRP (P = .011), and INR
(P = .042) were all signiﬁcantly associated with overall
survival on univariate analysis. However, only the platelet
count (P = .048), neutrophil count (P = .046), and CRP
(P = .016) demonstrated a signiﬁcant association with
disease-free survival. CRP data were only available for 35 of
the 140 patients in this study. Two patients with a CRP >
250 were excluded from the univariate CRP analysis as these
represented patients with an underlying infective process.
Data on preoperative CEA were only available for 58 of the
140 patients in the study. No signiﬁcant association between
CEA and survival was observed on univariate analysis when
modelling CEA as a continuous prognostic variable (Cox,
P = .954). However, when CEA data were dichotomised into
groups (using a cutoﬀ v a l u eo f1 0 n g / m L )t h eg r o u pw i t h
an elevated CEA exhibited a trend towards poorer survival
(log rank, P = .049). Because of the incomplete data for
bothpreoperativeCEAandCRP,neitherofthesefactorswere
included in the subsequent multivariate model.HPB Surgery 3
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Figure 1: Kaplan-Meier survival curves for illustration of the relationship between the haematological parameters of interest and overall
survival. (a) Kaplan-Meier survival curve to illustrate the signiﬁcant relationship between an increased preoperative lymphocyte count and
shorter overall survival. (b) Kaplan-Meier survival curve to illustrate the relationship between an increased preoperative neutrophil count
and shorter overall survival. (c) Kaplan-Meier survival curve to illustrate the signiﬁcant relationship between an increased preoperative
platelet count and shorter overall survival.
When analysed in a univariate model, disease-free inter-
val did not exhibit any signiﬁcant relationships with either
overall or disease-free survival following resections of CRLM
(HR = 1.000 (95% CI 0.996–1.003); P = .853, HR = 0.997
(95% CI 0.993–1.003); P = .177, resp.). The presence of
a synchronous CRLM also did not exhibit any signiﬁcant
relationship with either disease free or overall survival (P =
.983, .936, resp.) on univariate analysis.
Median survival times according to histopathological
tumour characteristics are shown in Table 3.O n l yr e s e c t i o n
margin involvement exhibited a signiﬁcant relationship with
overall survival. However, both nodal involvement and
bilobar disease demonstrated a clear trend towards less
favourable overall survival. Bilobar involvement and margin
status also both demonstrated a signiﬁcant association with
disease-free survival.4 HPB Surgery
Table 1: Demographic and tumour characteristics from resected
CRLM.
Number of patients analysed 140
Median age 67 years
(range) (33–82)
Male : Female 96 : 44
Synchronous : Metachronous 62 : 78
Unilobar : Bilobar disease 85 : 55
Resection margin
Clear : not clear 132 : 8
Hepatic lymph node
Involved : not involved 132 : 8
Recurrence following hepatic resection
Yes : no 71: 69
Adjuvant chemotherapy
Yes : no 47 : 55
Unknown 38
Dukes stage
A:B:C:D 8:4 5:8 5:2
Table 4 demonstratestheresultsofamultivariateanalysis
including both the haematological and histopathological
parameters of interest. These results indicate that both
the preoperative platelet and neutrophil count as well as
resection margin involvement and hepatic lymph node
involvement continue to demonstrate a signiﬁcant associa-
tionwithoverallsurvival.Resectionmargininvolvementand
bilobar disease also proved to be signiﬁcant predictors of
disease free survival.
4. Discussion
4.1. CRLM and Prognostic Markers of Survival. Prognostic
factors commonly reported in the setting of resected CRLM
include stage of the primary tumour, preoperative CEA
level, disease free interval, size and number of hepatic
metastases, the presence of extrahepatic disease, resection
margin involvement, lymph node invasion, and the presence
of bilobar liver disease [23, 24]. It is clear that these crude
morphologic and chronologic factors are inadequate, and
furtherprognosticindicatorsthatreﬂecttumourbiologyand
theinteractionbetweenthetumouranditshostarerequired,
not only to help with prognostic information, but for a role
in identifying possible therapeutic targets in future research
studies.
4.2. The Blood Count as a Prognostic Factor in Malig-
nancy. Numerousinvestigationshavereportedarelationship
between increased preoperative blood platelet count and
a poor prognosis in patients with malignant tumours,
including gastric cancer, oesophageal cancer, gynaecolog-
ical malignancies, and bronchial cancers [8–13]. Brown
et al. have reported preoperative platelet count to be an
independent predictor of prognosis following resections for
adenocarcinoma of the pancreas [14]. Similar relationships
have been identiﬁed in gastric and primary colorectal cancer
[9, 12].
Less is known about the association of preoperative
peripheral blood leucocyte subsets and prognosis in patients
with malignant disease. A study on metastatic gastric cancer
identiﬁed that pretreatment absolute granulocyte count of
<6000/mm3,l y m p h o c y t ec o u n to f>1500/mm3, and mono-
cyte count of 3000–9000/mm3 were independent predictors
of poor prognosis [16] .Ah i g hp r e o p e r a t i v el y m p h o c y t e
count carries a worse prognosis in those with breast cancer
[17] but was associated with a good prognosis in epidermoid
carcinoma of the head and neck [25]. A preoperative
monocyte count >300/mm3 was found to be a predictor of
poor prognosis following liver resections for hepatocellular
carcinoma[23]and CRLM[24].However,arelationship was
not identiﬁed with Lymphocyte count.
C-Reactive Protein (CRP), a marker of the systemic
inﬂammatory response, was shown to be inversely correlated
to prognosis in patients with malignant disease and has been
identiﬁed as an independent predictor of poor prognosis
in those undergoing resections for CRLM [20]. The same
relationship has been identiﬁed in patients with oesophageal
cancer[19]andprimarycolorectalcancer[18].International
Normalised Ratio (INR), a measure of the extrinsic pathway
of coagulation, is related to the concentration of VEGF in
patients who have had surgical cytoreduction for advanced
ovarian cancer [26].
In this study, we have attempted to place the relatively
easily measurable haematological parameters as predictive
markers within the context of other known blood borne
predictive markers of outcome (CEA and CRP), following
resection of colorectal liver metastases. Our study has identi-
ﬁed a high preoperative platelet count and neutrophil counts
and has identiﬁed resection margin involvement and hepatic
lymph node involvement to be independent predictors of
a poorer overall prognosis for patients in this study group.
This data also suggests that high preoperative CRP level
may hold an inverse relationship to both overall and disease
free survival; however, as the data was incomplete, inclusion
in the ﬁnal multivariate model was not possible. Of the
variables analysed, only resection margin involvement and
bilobar liver disease were independent predictors of tumour
recurrence (disease free survival) in those undergoing liver
resection of CRLM for patients in this study group; however,
an elevated preoperative platelet count exhibited strong
relationshipwithashorterdiseasefreesurvivalbutthisfailed
to reach statistical signiﬁcance.
An elevated preoperative lymphocyte count and INR
exhibited a signiﬁcant univariate relationship with decreased
overall survival in patients undergoing resections of CRLM
in our series; however, these parameters did not prove to be
independent predictors of prognosis as they failed to reach
signiﬁcance on multivariate analysis.
4.3. The Link between the Blood Count and Angiogenesis.
An explanation for our ﬁndings may lie in the process of
tumour angiogenesis [27]. It is now widely believed thatHPB Surgery 5
Table 2: Univariate survival analysis of preoperative haematological parameters as prognostic covariates in resected CRLM (Cox
proportional hazards). (NB hazards ratio for continuous data reﬂects increase in relative risk of event with each incremental increase in
covariate value of 1 unit).
Overall survival Disease free survival
Median (range) Hazards ratio (95% CI) P Hazards ratio (95% CI) P
Platelet count 264 1.004 .013 1.003 .048
(×109/L) (129–576) (1.001–1.006) (1.000–1.005 )
Lymphocyte count 1.6 1.438 .022 1.336 .086
(×109/L) (0.5–5.0) (1.058–2.078) (0.960–1.861)
Neutrophil count 4.7 1.042 <.001 1.019 .046
(×109/L) (2–15) (1.031–1.054) (1.006–1.038)
Haemoglobin 13.6 0.964 .648 0.847 .022
(g/dL) (8.8–18) (0.824–1.128) (0.735–0.976)
INR 1.0 14.334 .042 1.130 .930
(0.8–1.4) (1.104–186.125) (0.076–16.822)
CRP∗ 7 1.019 .011 1.018 .016
(5–128) (1.004–1.032) (1.003–1.032)
CEA∗∗ 14.9 1.000 .954 1.001 .300
(0.0–1337) (0.999–1.001) (0.999–1.002)
∗Preoperative CRP data available for 33 patients only.
∗∗Preoperative CEA data available for 58 patients only.
Table 3: Univariate survival analysis of tumour characteristics as prognostic covariates in resected CRLM.
Overall survival Disease free survival
Median survival (Months) P Median survival (Months) P
Dukes stage
A+ B∗ 45 .241 28 .135
C+ D∗ 31 19
Unilobar versus bilobar 41 .143 30 .002
disease 31 17
Resection margin
Clear 41 .001 24 <.001
Not clear 12 8
Hepatic lymph nodes
Involved 42 .067 23 .809
Not involved 26 21
∗Due to the small number of patients with Dukes A and D tumours (n = 7a n dn = 2, resp.), those with Dukes A and B were grouped together for analysis
and survival times compared with Dukes C and D.
primarytumoursandmetastaticlesionscannotgrowbeyond
2 to 3mm in size in the absence of vascularisation [26]
regardless if this is secured by occasional “cooption” of
pre-existing capillaries [28] or by active angiogenesis [29].
The role of tumour angiogenesis is not only to ensure
continual metabolic and oxygen exchange but also to act
as an important source of paracrine stimulation [30]w h i c h
is achieved through endothelial cell-derived extracellular
matrix (ECM), proteases, and cytokines which regulate
tumour growth, survival, even invasion, and metastasis [30].
The onset of tumour angiogenesis, angiogenic switch, is the
result of a shift in balance between pro- and antiangiogenic
factors secreted not only by tumour cells but also by several
activated host stromal cells [31, 32]. Among these are
mast cells [33], resident macrophages [34], blood-borne
mononuclear leukocytes [35], and platelets [36, 37].
Vascular Endothelial Growth Factor (VEGF), a potent
angiogenic peptide with biologic eﬀects that include reg-
ulation of haematopoietic stem cell development, extra-
cellular matrix remodelling, and inﬂammatory cytokine
regeneration [38], is secreted locally by cancer cells and
by inﬂammatory cells in the blood, including platelets
and leucocytes [39–41]. Both VEGF and Platelet Derived
Endothelial Cell Growth Factor (PD-ECGF) are related to6 HPB Surgery
Table 4: Multivariate survival analysis of prognostic covariates in resected CRLM (Cox proportional hazards). (NB hazards ratio for
continuous data reﬂects increase in relative risk of event with each incremental increase in covariate value of 1 unit).
Overall survival Disease free survival
Hazards ratio P Hazards ratio P
(95% CI) (95% CI)
Dukes stage 1.115 (0.652–1.908) .691 1.170 (0.693–1.973) .557
Resection margin 4.008 (1.567–10.252) .004 6.599 (2.432–17.903) .002
Hepatic lymph nodes 2.709 (1.194–6.145) .017 1.732 (0.736–4.076) .208
Unilobar versus bilobar disease 1.452 (0.869–2.427) .154 1.968 (1.211–3.200) .006
Platelet count∗ (×109/L) 1.004 (1.002–1.007) .002 1.003 (1.000–1.005) .076
Lymphocyte count∗ (×109/L) 1.022 (0.731–1.429) .898 1.183 (0.809–1.731) .386
Neutrophil count∗ (×109/L) 1.043 (1.027–1.058) <.001 1.018 (0.995–1.041) .118
INR
∗ 20.331 (0.869–475.645) .061 1.813 (0.084–39.233) .609
∗Factors included as continuous covariates for Cox regression.
the vascular density and hence the angiogenic process in
solid tumours [42, 43]. VEGF is a potent mitogen for
endothelial cells and also increases vascular permeability.
PD-ECGF is a powerful chemotaxic agent for endothelial
cells in vivo. Both are powerful inducers of angiogenesis and
may act synergistically [42, 43].
High levels of VEGF and PD-ECGF are found in serum,
platelets, and leucocytes of patients with malignant disease
[37], when compared to those of normal individuals [40].
VEGFlevelsareevenhigherindisseminateddisease[41],and
elevated serum VEGF levels are an independent prognostic
factor in patients with colorectal cancer [43]. It is postulated
that the VEGF in the bloodstream is transported by blood
cells, including leucocytes and platelets [40–43]. The cells
of cancer patients contain greatly elevated amounts of this
major angiogenic growth factor, and this reservoir of VEGF
may have a role in tumour angiogenesis and metastases
formation.
Analternativeexplanationforourﬁndingsisthroughthe
linkbetweenchronicinﬂammationandcancerdevelopment.
Clinical and experimental data now clearly indicate that
persisting chronic inﬂammation signiﬁcantly contributes to
cancer development [44], and it is increasingly appreci-
ated that persistent humoral immune responses exacerbate
recruitment and activation of innate immune cells in
neoplastic microenvironments where they regulate tissue
remodelling, proangiogenic and prosurvival pathways that
together potentiate cancer development [45].
As most of the haematological parameters analysed in
this study exhibited a strong relation with overall survival,
but not with disease free survival one can question whether
these markers truly represent underlying tumour biology or
if they are purely markers of overall health of the patient
undergoing a major resection. As discussed earlier our
study has provided some interesting observations which will
require validation in larger series of patients before a ﬁrm
conclusion on their role in prognostication can be reached.
In the not too distant future, understanding tumour
biology will probably yield more eﬀective predictive data
than the present reliance on morphologic description [23,
24]. Cetuximab, a monoclonal antibody targeted against the
EGF receptor which acts to inhibit the k-ras pathway, shows
promise as agents to downstage CRLM preoperatively in
unresectable lesions [46].
In summary, our study has identiﬁed that an increased
preoperative platelet count and neutrophil count are inde-
pendent predictors of a worse prognosis in our study
population of patients undergoing hepatic resections for
CRLM. These ﬁndings merit validation in a larger patient
series alongside CEA and CA19-9 as additional prognostic
covariates which could not be adequately analysed in the
present study.
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